CN105669851B - 鳐血管生成抑制因子1的适配子k6及其筛选方法和应用 - Google Patents
鳐血管生成抑制因子1的适配子k6及其筛选方法和应用 Download PDFInfo
- Publication number
- CN105669851B CN105669851B CN201610098919.8A CN201610098919A CN105669851B CN 105669851 B CN105669851 B CN 105669851B CN 201610098919 A CN201610098919 A CN 201610098919A CN 105669851 B CN105669851 B CN 105669851B
- Authority
- CN
- China
- Prior art keywords
- aptamer
- functional areas
- ray angiostatin
- ray
- albumen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000012936 Angiostatins Human genes 0.000 title claims abstract description 34
- 108010079709 Angiostatins Proteins 0.000 title claims abstract description 34
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 title claims abstract description 33
- 108091023037 Aptamer Proteins 0.000 title abstract description 27
- 238000012216 screening Methods 0.000 title description 17
- 238000000034 method Methods 0.000 title description 14
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 23
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 abstract description 7
- 238000001514 detection method Methods 0.000 abstract description 5
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 abstract description 4
- 108020004414 DNA Proteins 0.000 description 36
- 102000053602 DNA Human genes 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000007846 asymmetric PCR Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 3
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010058905 CD44v6 antigen Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- -1 SEQ ID No.2-11 Natural products 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- ILXAOQAXSHVHTM-UHFFFAOYSA-M sodium;2-amino-2-(hydroxymethyl)propane-1,3-diol;chloride Chemical compound [Na+].[Cl-].OCC(N)(CO)CO ILXAOQAXSHVHTM-UHFFFAOYSA-M 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1048—SELEX
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
适配子名称 | 亲和力 | 适配子名称 | 亲和力 |
K2 | 0.62 | K15 | 0.43 |
K6 | 0.53 | K16 | 0.51 |
K9 | 0.50 | K17 | 0.59 |
K10 | 0.47 | K19 | 0.62 |
K14 | 0.60 | K20 | 0.49 |
适配子名称 | Kd值(nM) | 适配子名称 | Kd值(nM) |
K2 | 35.27 | K15 | 59.23 |
K6 | 51.73 | K16 | 38.97 |
K9 | 43.81 | K17 | 44.83 |
K10 | 50.46 | K19 | 34.57 |
K14 | 35.89 | K20 | 47.81 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610098919.8A CN105669851B (zh) | 2014-06-06 | 2014-06-06 | 鳐血管生成抑制因子1的适配子k6及其筛选方法和应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410249737.7A CN104031137B (zh) | 2014-06-06 | 2014-06-06 | 鳐血管生成抑制因子1的适配子及其筛选方法和应用 |
CN201610098919.8A CN105669851B (zh) | 2014-06-06 | 2014-06-06 | 鳐血管生成抑制因子1的适配子k6及其筛选方法和应用 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410249737.7A Division CN104031137B (zh) | 2014-06-06 | 2014-06-06 | 鳐血管生成抑制因子1的适配子及其筛选方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105669851A CN105669851A (zh) | 2016-06-15 |
CN105669851B true CN105669851B (zh) | 2019-05-21 |
Family
ID=56304901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610098919.8A Active CN105669851B (zh) | 2014-06-06 | 2014-06-06 | 鳐血管生成抑制因子1的适配子k6及其筛选方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105669851B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006096754A2 (en) * | 2005-03-07 | 2006-09-14 | Archemix Corp. | Stabilized aptamers to psma and their use as prostate cancer therapeutics |
CN101724631A (zh) * | 2008-11-03 | 2010-06-09 | 广东海洋大学 | 鳐血管生成抑制因子1功能区的制备及在防治肿瘤药物中的应用 |
CN103060326A (zh) * | 2012-12-17 | 2013-04-24 | 集美大学 | 6条寡核苷酸序列及其应用 |
-
2014
- 2014-06-06 CN CN201610098919.8A patent/CN105669851B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006096754A2 (en) * | 2005-03-07 | 2006-09-14 | Archemix Corp. | Stabilized aptamers to psma and their use as prostate cancer therapeutics |
CN101724631A (zh) * | 2008-11-03 | 2010-06-09 | 广东海洋大学 | 鳐血管生成抑制因子1功能区的制备及在防治肿瘤药物中的应用 |
CN103060326A (zh) * | 2012-12-17 | 2013-04-24 | 集美大学 | 6条寡核苷酸序列及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105669851A (zh) | 2016-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104109194B (zh) | Sfrp1蛋白的适配子及其筛选方法和应用 | |
CN103966224B (zh) | 一种适配子及其筛选方法和应用 | |
Dastjerdi et al. | Generation of an enriched pool of DNA aptamers for an HER2‐overexpressing cell line selected by Cell SELEX | |
CN102605075B (zh) | 一组能同时识别哈维氏弧菌和溶藻弧菌的寡核苷酸序列及其制备方法 | |
CN101624636B (zh) | 传染性脾肾坏死病毒的lamp-lfd检测方法 | |
CN107058329B (zh) | 一种特异性结合新城疫病毒的核酸适配体及其筛选方法和应用 | |
CN105541986B (zh) | 鳐血管生成抑制因子1的适配子k9及其筛选方法和应用 | |
CN105753987A (zh) | 抗il-4r单链抗体的制备方法及其在抗肿瘤上的应用 | |
CN102839181A (zh) | 一种胃癌细胞的核酸适配体序列及用途 | |
CN102766693B (zh) | 可用于检测人肝癌细胞株smmc-7721的核酸适体及其筛选方法和应用 | |
WO2010091144A1 (en) | Compositions, methods, and kits for identifying candidate molecules from encoded chemical libraries | |
CN102010865B (zh) | 一种特异识别单核细胞增生李斯特菌的寡核苷酸适配子 | |
He et al. | Single-primer-limited amplification: A method to generate random single-stranded DNA sub-library for aptamer selection | |
CN104498500A (zh) | 一种识别耐阿霉素乳腺癌细胞的核酸适体及其筛选方法和应用 | |
RU2019103083A (ru) | МУТАЦИИ ErbB3 ПРИ РАКЕ | |
KR101535892B1 (ko) | 살모넬라 티피뮤리움 균주의 ompC단백질에 대해 결합하는 RNA 앱타머 | |
CN105646695B (zh) | 鳐血管生成抑制因子1的适配子k16及其筛选方法和应用 | |
CN105669852B (zh) | 鳐血管生成抑制因子1的适配子k10及其筛选方法和应用 | |
CN105669851B (zh) | 鳐血管生成抑制因子1的适配子k6及其筛选方法和应用 | |
CN105713081B (zh) | 鳐血管生成抑制因子1的适配子k17及其筛选方法和应用 | |
CN103667521B (zh) | 一组用于检测虹彩病毒的引物及检测方法 | |
CN102732972A (zh) | 一个核酸适配子筛选文库 | |
CN106497931B (zh) | 一种针对Her3ECD的ssDNA适配体及其在诊断治疗HER3相关疾病中的应用 | |
CN105506150B (zh) | 一种emsa方法及其探针和该探针的制备方法 | |
CN107988349A (zh) | Kras基因检测引物组、试剂盒及检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190425 Address after: 510030 Room 3803, No. 307, Central Guangzhou Avenue, Yuexiu District, Guangzhou City, Guangdong Province Applicant after: Guangzhou Zhongyu Medical Biotechnology Co.,Ltd. Address before: 310027 Zhejiang University, 38 Xihu District Zhejiang Road, Zhejiang University, Zhejiang Applicant before: Zhang Yong |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Aptamers K6 of ray angiogenesis inhibitor 1 and screening method and application of aptamers Effective date of registration: 20200508 Granted publication date: 20190521 Pledgee: Development Zone sub branch of Bank of Guangzhou Co.,Ltd. Pledgor: Guangzhou Zhongyu Medical Biotechnology Co.,Ltd. Registration number: Y2020980002036 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210514 Granted publication date: 20190521 Pledgee: Development Zone sub branch of Bank of Guangzhou Co.,Ltd. Pledgor: Guangzhou Zhongyu Medical Biotechnology Co.,Ltd. Registration number: Y2020980002036 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Aptamer K6 of skate angiogenesis inhibitor 1 and its screening method and Application Effective date of registration: 20210517 Granted publication date: 20190521 Pledgee: Development Zone sub branch of Bank of Guangzhou Co.,Ltd. Pledgor: Guangzhou Zhongyu Medical Biotechnology Co.,Ltd. Registration number: Y2021980003708 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220526 Granted publication date: 20190521 Pledgee: Development Zone sub branch of Bank of Guangzhou Co.,Ltd. Pledgor: Guangzhou Zhongyu Medical Biotechnology Co.,Ltd. Registration number: Y2021980003708 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Aptamer K6 of ray angiogenic inhibitor 1 and its screening method and Application Effective date of registration: 20220531 Granted publication date: 20190521 Pledgee: Development Zone sub branch of Bank of Guangzhou Co.,Ltd. Pledgor: Guangzhou Zhongyu Medical Biotechnology Co.,Ltd. Registration number: Y2022980006764 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230609 Granted publication date: 20190521 Pledgee: Development Zone sub branch of Bank of Guangzhou Co.,Ltd. Pledgor: Guangzhou Zhongyu Medical Biotechnology Co.,Ltd. Registration number: Y2022980006764 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Adaptor K6 of Ray Angiogenesis Inhibitor 1 and Its Screening Method and Application Effective date of registration: 20230627 Granted publication date: 20190521 Pledgee: Development Zone sub branch of Bank of Guangzhou Co.,Ltd. Pledgor: Guangzhou Zhongyu Medical Biotechnology Co.,Ltd. Registration number: Y2023980045864 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |